Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 7

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 7
---
 maintain an Internet
website at www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of this prospectus.
We have included our website address in this prospectus as an inactive textual reference only and not as an active hyperlink.

<div align='center'>S-2</div>

The Offering

| Common stock we are offering under this prospectus supplement       |     | 3,000,000 shares of common stock.                                                                                                                                                                                                                                                     |
| Common stock to be outstanding after giving effect to this offering |     | 26,585,258 shares of common stock.                                                                                                                                                                                                                                                    |
| Use of proceeds                                                     |     | We estimate the net proceeds from this offering will be approximately $17.4 million, after deducting Placement Agent fees and estimated offering expenses payable by us.                                                                                                              |
|                                                                     |     | We intend to use the net proceeds from this offering for general corporate purposes and working capital. See “Use of Proceeds.”                                                                                                                                                       |
| Risk factors                                                        |     | Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page S-4 of this prospectus supplement and on page 5 of the accompanying prospectus and under a similar heading in any documents included or incorporated by reference herein or therein. |
| Nasdaq Capital                                                      
 Market symbol                                                       |     | Our common stock is listed on The Nasdaq Capital Market under the symbol “INMB.”                                                                                                                                                                                                      |

Unless we indicate otherwise, all information in this prospectus supplement, including the number of shares of common stock to be outstanding immediately after this offering as shown above, is based on 23,585,258 shares of common stock outstanding as of June 27, 2025, and excludes:

| ● | 7,303,307 shares of our common stock issuable upon the exercise of outstanding stock options, at a weighted average exercise price of $8.28 per share, 5,379,014 of which are exercisable at a weighted average exercise price of $8.78 per share; |

| ● | 3,944,138 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $7.75 per share; |

| ● | 2,521,243 additional shares of our common stock available for future issuance under our amended and restated INmune Bio Inc. 2021 stock incentive plan; and                                                     |
| ● | 654,847 shares